Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03810339 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03810339 · ClinicalTrials.gov record · last posted 2026-04-23

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Name: Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors — clinical trial record (NCT03810339)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorSun Yat-sen University

Started2019-01-15

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.

Protocol amendment history 1 change detected by DataLookout

2026-04-24

Trial sites expanded: 1 → 4 locations

Trial Details

NCT Number	NCT03810339
Lead Sponsor	Sun Yat-sen University
Conditions	Solid Tumor, Advanced Cancer
Enrollment	35 participants
Start Date	2019-01-15
Primary Completion	2028-01-15 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-23